Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids
- 1 May 2015
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 96, 340-359
Abstract
No abstract availableKeywords
Funding Information
- NIH (R01CA131217, R01GM084188)
This publication has 58 references indexed in Scilit:
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myelomaBlood, 2012
- High-Throughput Screening of Small Molecule Libraries using SAMDI Mass SpectrometryACS Combinatorial Science, 2011
- Peptide Arrays Identify Isoform-Selective Substrates for Profiling Endogenous Lysine Deacetylase ActivityACS Chemical Biology, 2010
- Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin AJournal of the American Chemical Society, 2010
- HDAC expression and clinical prognosis in human malignanciesCancer Letters, 2009
- Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxideMolecular Cancer Therapeutics, 2009
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- A Role for the Proton-coupled Folate Transporter (PCFT-SLC46A1) in Folate Receptor-mediated EndocytosisJournal of Biological Chemistry, 2009
- Role for Histone Deacetylase 1 in Human Tumor Cell ProliferationMolecular and Cellular Biology, 2007
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006